CNN takes a look at the commercial end of the
stem cell research and development pipeline: "Two biotechs,
Cytori Therapeutics and
Osiris Therapeutics, each hope to get their experimental stem cell products approved by the Food and Drug Administration and into the U.S. market by 2008. ... Cytori is planning to launch its first stem cell medical device in Europe this year [using] stem cell technology to rebuild breast tissue in cancer survivors. ... Osiris, [currently] has the only stem cell-based product that's been
approved by the FDA. OsteoCell, which stimulates bone growth and is already on the U.S. market, is actually considered an implant rather than a drug or device. ... Prochymal, a potential treatment for acute
Graft vs. Host Disease (also known as GVHD) and
Crohn's disease, is in late-stage trials." Applications are narrow, incremental and
slow in coming because the
regulatory regime forces development in this direction; this becomes the cost-effective path, rather than
anything more ambitious.
View the Article Under Discussion:
http://money.cnn.com/2007/04/05/news/companies/stemcell/index.htm
Read More Longevity Meme Commentary:
http://www.longevitymeme.org/news/